{'fraction_non_alphanumeric': 0.057766367137355584, 'fraction_numerical': 0.03465982028241335, 'mean_word_length': 4.777777777777778, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Experimental induction of hepatomas, mammary tumors, and other tumors with metronidazole in noninbred Sas:MRC(WI)BR rats.

Metronidazole, a chemotherapeutic agent against trichomonas infection, was tested for carcinogenicity in noninbred Sas:MRC(WI)BR rats. Three groups were given the drug for life at dose levels of 0.6%, 0.3%, and 0.06% in a powdered diet. The incidence of mammary tumors (P less than 0.020) and hepatomas (P less than 0.050) increased significantly among females given the highest dose (0.6%). Also, the rates of Leydig cell tumors of the testes (P less than 0.040) and pituitary adenomas (P less than 0.040) were statistically significant among males given the highest dose (0.6%). Results are discussed in light of a possible hazard of this drug to humans.